Forwarding the survey from ARDAT. Interested parties please fill the attached form and email to Graham Hughes (ARDAT coordinator; [email protected]) directly.
Hello,
We are distributing the attached survey in an effort to collect responses from the community for ARDAT (Accelerating Research & Development for Advanced Therapies, http://ardat.org/). The survey is specifically aimed to understand the clinical factors around pre-existing immunity limiting patient access to ATMP therapy, and adaptive immune responses affecting product safety, efficacy and persistence.
Graham Hughes (ARDAT coordinator; [email protected]) will collect all sheets from the contributing parties (ARDAT partners, AAPS members, IQ members) and will forward anonymized sheets to the ARDAT working group for evaluation of the questionnaire. ARDAT plans to publish the results listing all contributing parties without disclosing their detailed contribution.
If possible, please fill out the questionnaire and follow the instructions listed in the attached excel sheet.
------------------------------
Yi Wen Ph.D.
Sr. Director
Eli Lilly and Company
Indianapolis IN
[email protected]Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
------------------------------